I

Illawarra Shoalhaven Local Health District | Illawarra Diabetes Service - Clinical Trial & Research Unit

Research site

(Unclaimed)

Location

Level 2/304 Crown St, Wollongong, New South Wales, Australia

Site insights

Top conditions

Top treatments

Tirzepatide

LY3298176

Sulfonylurea

Apixaban

Avelumab

Metformin

Radium-223 Dichloride

Finerenone

Xofigo

Parent organization

This site is a part of Illawarra Shoalhaven Local Health District

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 8 total trials

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CVOT)

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardio...

Active, not recruiting

Type 2 Diabetes Mellitus

Drug: Tirzepatide

Drug: Dulaglutide

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD)

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finere...

Active, not recruiting

Non-diabetic Chronic Kidney Disease

Drug: Finerenone (BAY94-8862)

Drug: Placebo

Guideline Oriented Approach to Lipid Lowering in Asia-Pacific (GOAL-ASIA)

Multinational, patient-level randomised, multi-phase standard-of-care control arm, parallel group, implementation study.Patients will be recruited du...

Enrolling

Acute Coronary Syndrome

Hypercholesterolemia

Behavioral: Early Intervention

Investigation of Radium-223 Dichloride (Xofigo), a Treatment That Gives Off Radiation That Helps Kill Cancer Cells, Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy, NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and new (novel) anti-hormonal (NAH) therapy work in participan...

Active, not recruiting

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Drug: NAH therapy

Drug: Radium-223 dichloride (Xofigo, BAY88-8223)

Trial sponsors

U

S

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms